Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease (IMAGE)
Caption
MASLD is one of the pressing public health issues; yet, unfortunately, there is a scarcity of available pharmacological management options. GLP-1RAs have transformed the treatment landscape for diabetes and obesity, making them promising candidates for MASLD. GLP-1RAs contribute to metabolic adjustments in MASLD by controlling fat deposition, inflammation, and potentially fibrosis. However, more evidence is needed to clarify their systemic effects and controversial direct hepatic benefits. GLP-1RAs and co-agonists have shown promising outcomes in the clinical management of MASLD. In the future, GLP-1RAs and co-agonists may serve as supplements for personalized therapies targeting metabolic control, anti-inflammation, and even anti-fibrosis effects. Moreover, their potential as monotherapy for sequential control of MASLD warrants further investigation.
Credit
Lun-Gen Lu, Ming-Wang Wang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC